Contribute Try STAT+ Today

D.C. Diagnosis is STAT’s weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox.

Pharma’s ready to rumble … over patents

There’s a fight brewing over legislation meant to rein in the over-patenting of drugs. Drug makers are trying to gut a bill from Sens. John Cornyn (R-Texas) and Richard Blumenthal (D-Conn.) that would open up drug makers to Federal Trade Commission lawsuits when they’re suspected of product hopping (where drug makers introduce a new, slightly tweaked version of a drug to thwart competition) and patent thicketing (where drug makers file dozens or even hundreds of patents on a single drug to keep competitors off the market well beyond the exclusivity period awarded by the FDA).

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy